video

Carol Jarvis, a professional musician who was diagnosed with Hodgkin lymphoma in 2004, talks about living in remission with the disease. Carol shares her insights into her journey from diagnosis to remission as part of her treatment journey where following an ASCT she received ADCETRIS (brentuximab vedotin) and subsequent other therapies.

Listen to Dr Sharmistha Ghosh discuss the management of cardiac adverse events, including bradycardia and hypertension, which may be experienced in patients with ALK+ aNSCLC who take ALUNBRIG.

Dr Ghosh explains the recommended dose modifications for ALUNBRIG in cases of bradycardia and hypertension, as well as her clinical experience of managing these adverse events.

Listen to Dr Yvonne Summers provide her opinion on pill burden and the convenience of once daily dosing during treatment with ALUNBRIG for ALK+ aNSCLC.

ALK+, anaplastic lymphoma kinase positive; aNSCLC, advanced non-small cell lung cancer. 

Listen to Dr Sharmistha Ghosh discuss the management of skin toxicities which may occur in patients with ALK+ aNSCLC who take ALUNBRIG.

Dr Ghosh explains the recommended dose modifications for ALUNBRIG if patients experience skin toxicities as well as the guidance relating to photosensitivity and photodermatosis.

ALK+, anaplastic lymphoma kinase positive; aNSCLC, advanced non-small cell lung cancer.

Listen to Prof Samreen Ahmed highlight the impact of brain metastases on quality of life in patients with ALK+ aNSCLC and why intracranial monitoring and management is important in these patients. 

Prof Ahmed reviews ALUNBRIG’s intracranial efficacy vs crizotinib in patients with ALK+ aNSCLC from the pivotal ALTA-1L trial and discusses why ALUNBRIG could be a suitable treatment option in patients with ALK+ aNSCLC.

Listen to Dr Sharmistha Ghosh provide an overview of the results from the ALTA-1L retrospective chart review study which provides insight into the use of subsequent systemic anticancer treatments in patients with ALK+ aNSCLC following discontinuation of 1L ALUNBRIG from the ALTA-1L trial. 

Dr Ghosh discusses specific data relating to lorlatinib, as the most commonly used 2L ALK TKI used within the retrospective chart review, and as a licensed treatment option after progression on 1L ALUNBRIG in the UK.

Listen to Prof Samreen Ahmed review ALUNBRIG’s systemic efficacy from the ALTA-1L trial which compared first-line use of ALUNBRIG vs crizotinib in patients with ALK+ aNSCLC. 

Using a real-world example from the ALTA-1L study, Prof Ahmed highlights the importance of ALUNBRIG as a first-line treatment option in improving symptoms of patients with ALK+ aNSCLC. 

Listen to Dr Yvonne Summers discuss the current unmet needs of patients with ALK+ aNSCLC, including the negative impact of brain metastases on the daily lives of these patients. 

Dr Summers provides an overview of the ALUNBRIG health-related QOL data from the ALTA-1L study in patients with ALK+ aNSCLC and how these results compare with her real-world experience in clinical practice.